Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Investment Income (2020 - 2023)

Insight Molecular Diagnostics' Non Operating Investment Income history spans 4 years, with the latest figure at -$69000.0 for Q4 2023.

  • For Q4 2023, Non Operating Investment Income fell 592.86% year-over-year to -$69000.0; the TTM value through Dec 2023 reached -$61000.0, up 87.05%, while the annual FY2023 figure was -$61000.0, 87.05% up from the prior year.
  • Non Operating Investment Income for Q4 2023 was -$69000.0 at Insight Molecular Diagnostics, up from -$89000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $315000.0 in Q4 2020 and bottomed at -$330000.0 in Q1 2022.
  • The 4-year median for Non Operating Investment Income is -$7000.0 (2021), against an average of -$312.5.
  • The largest YoY upside for Non Operating Investment Income was 981.25% in 2021 against a maximum downside of 790.0% in 2021.
  • A 4-year view of Non Operating Investment Income shows it stood at $315000.0 in 2020, then crashed by 106.03% to -$19000.0 in 2021, then skyrocketed by 173.68% to $14000.0 in 2022, then tumbled by 592.86% to -$69000.0 in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Non Operating Investment Income are -$69000.0 (Q4 2023), -$89000.0 (Q3 2023), and -$24000.0 (Q2 2023).